Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This product is a **combination probiotic formulation** containing the bacterial strains *Lactobacillus acidophilus*, *Bifidobacterium lactis*, *Bifidobacterium longum*, and *Bifidobacterium bifidum*. These strains are naturally occurring, Gram-positive, lactic acid-producing bacteria commonly found in the human gastrointestinal tract. They are administered as **probiotics** to support intestinal flora balance, improve digestive health, and modulate immune responses. *L. acidophilus* and species of *Bifidobacterium* play roles in fermenting carbohydrates, producing lactic acid, reducing intestinal inflammation, and regulating immune signaling pathways such as NF-κB and MAPK. They have been investigated for benefits in **irritable bowel syndrome (IBS)**, inflammatory bowel disease (IBD), supporting barrier function, and other digestive disturbances. The mechanism includes modulation of gut microbiota, enhancement of mucosal integrity, production of bioactive metabolites, and anti-inflammatory signaling via increased toll-like receptor 2 (TLR2) and decreased cytokine production[1][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lactobacillus acidophilus + bifidobacterium lactis + bifidobacterium longum + bifidobacterium bifidum.